Shiew‐Mei Huang

United States Food and Drug Administration

Also affiliated with Center for Drug Evaluation and Research

Pharmacology, Toxicology and PharmaceuticsMedicineComputer Science

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 3 papers. Top paper: “3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration”.

3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration

Clinical and Translational Science(2021)10.1111/cts.13066

N/A

0.803DataRank · unranked

211 citations

Paul C. Brown, Edwin C.Y. Chow, Lorna Ewart, Stephen S. Ferguson, Suzanne Fitzpatrick +16 more

Do Inhibitory Metabolites Impact DDI Risk Assessment? Analysis of in vitro and in vivo Data from NDA Reviews Between 2013 and 2018

Clinical Pharmacology & Therapeutics(2021)10.1002/cpt.2259

N/A

0.425DataRank · unranked

16 citations

Xinning Yang, Jingjing Yu, Hristina Dimova, Shiew‐Mei Huang, Isabelle Ragueneau‐Majlessi +2 more

Roadmap to 2030 for Drug Evaluation in Older Adults

Clinical Pharmacology & Therapeutics(2021)10.1002/cpt.2452

N/A

0DataRank · unranked

70 citations

Janice B. Schwartz, Patricia W. Slattum, Sandra Lau, Daphne Guinn, Rajanikanth Madabushi +20 more